Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1282-1286

  Ugurel, S ^a   Rappl, G ^a   Tilgen, W ^a   Reinhold, U ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANTIGENS, CD95; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0034901557     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fas and Fas ligand: A death factor and its receptor
2. Fas and FasL in the homeostatic regulation of immune responses
3. Signaling events in T lymphocytes leading to cellular activation or programmed cell death
4. The host-tumor immune conflict: From immunosuppression to resistance and destruction
5. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness
6. The Fas counterattack: Cancer as a site of immune privilege
7. Fas and Fas ligand interactions suppress melanoma lung metastasis
8. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
9. Soluble Fas/APO-1 in tumor cells: A potential regulator of apoptosis?
10. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
11. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
12. Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome
13. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias
14. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy
15. Prognostic significance of soluble Fas in the serum of patients with bladder cancer
16. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
17. Circulating soluble Fas concentration in breast cancer patients
18. Soluble Fas in serum from patients with renal cell carcinoma
19. Serum soluble Fas levels in ovarian cancer
20. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative, and myelodysplastic syndromes
21. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: Absence of prognostic correlations
22. Soluble CD95 (Fas/APO-1) in malignant glioma: (No) implications for CD95-based immunotherapy?
23. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
24. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
25. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-γ
26. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release
27. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
28. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95)
29. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
30. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma
31. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines
32. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
33. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles
34. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells